Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 7;9(8):976. doi: 10.3390/biomedicines9080976

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The combined treatment of hydralazine and enzalutamide augmented DNA damage (here represented by the tail moment measurement) in PCa (prostate cancer) cells. The presented data are representative of at least 500 cells analysed. The mean ± standard deviation were as follows: LNCaP V—0.96 ± 5.33; LNCaP H—4.23 ± 10.8; LNCaP E—6.19 ± 13.9; LNCaP H+E—4.53 ± 12.9; PC-3 V—0.36 ± 2.84; PC-3 H—3.36 ± 10.84; PC-3 E—5.35 ± 14.18; PC-3 H+E—5.34 ± 14.67; C4-2 V—0.66 ± 3.31; C4-2 H—4.74 ± 13.33; C4-2 E—4.45 ± 12.46; C4-2 H+E—7.42 ± 16.85 (V—vehicle, H—hydralazine, E—enzalutamide, H+E—combination of hydralazine and enzalutamide).